Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies

Novo Nordisk today announced clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec, an ultra long-acting basal insulin, to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes. Basal-bolus treatment is comprised of treatment with long-acting (basal) insulin and a rapid-acting (bolus) insulin, and in both studies insulin aspart was used as the bolus insulin. These studies, as well as three additional studies reported today, are part of the largest clinical development programme ever conducted for an insulin. Further information: Media: Investors: Mike Rulis Klaus Bülow Davidsen Tel: (+45) 4442 3573 Tel: (+45) 4442 3176 [email protected] [email protected] Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 [email protected] Jannick Lindegaard Tel: (+45) 4442 4765 [email protected] In North America: In North America: Ken Inchausti Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 [email protected] [email protected] Company Announcement no 71 / 2010

The release as fetched from its publisher. novonordisk.com ↗